{"id":809324,"date":"2025-02-05T16:05:05","date_gmt":"2025-02-05T21:05:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/"},"modified":"2025-02-05T16:05:05","modified_gmt":"2025-02-05T21:05:05","slug":"ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/","title":{"rendered":"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">COPENHAGEN, Denmark, Feb.  05, 2025  (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results.<\/p>\n<p>Those who would like to participate may access the live webcast <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AJHYTHYEaJU7JW5Tn0mMACD1HRb4elBcUT6e5JXCyyRp93akWVycZmflU1Ph-SQ3a32kAWGLtVg5KbgALcxS5sw2zzalRdlDWmYvAS5zA38=\" rel=\"nofollow\" target=\"_blank\">here<\/a>, or register in advance for the teleconference <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AJHYTHYEaJU7JW5Tn0mMADRbuKCoNKSGIhU5EhS5EBwlksC4x9txwyoVLCgow2Ypctxbw0qFUa3Ho-LaPrQr4rRoy80GjREbAD0z1LQJ0bl0N6QnDaWG4qwQRZAUCuAmGUNVbwej123uAaQxXyyvIA==\" rel=\"nofollow\" target=\"_blank\">here<\/a>. The link to the live webcast will also be available on the Investors &amp; News section of the Ascendis Pharma website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JaKvMXeQybnPqUqCUa_Dl1atH69PQy00ymzO-0QyxwRV-o6ZUfSZHh6Lnoywb9Ab39gXIecyA9zWZbVskQgXT281FiHgbViPrNvVQrsiBBDsY5hOYbLSUrd-7Ih6r-Yz\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.ascendispharma.com<\/a>. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days.<\/p>\n<p>\n        <strong>About Ascendis Pharma A\/S<\/strong><br \/>\n        <br \/>Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients\u2019 lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tGn7KNu0pxofuv5IxzvHUBQNgoGWv2nnsUsHd1NiC2z6b8f04AhsXHcjfqFOc0hi7VesYtJrcmRfKDn88DFvNxbwHFnsWFZygZU7C0BV40M=\" rel=\"nofollow\" target=\"_blank\">ascendispharma.com<\/a> to learn more.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis\u2019 future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis\u2019 ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company and (ii) Ascendis\u2019 use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis\u2019 products and product candidates; unforeseen safety or efficacy results in Ascendis\u2019 development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis\u2019 development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis\u2019 business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis\u2019 ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis\u2019 business in general, see Ascendis\u2019 prospectus supplement filed on September 20, 2024 and Ascendis\u2019 current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 7, 2024. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.<\/p>\n<p>\n        <em>Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA\u00ae, and YORVIPATH\u00ae are trademarks owned by the Ascendis Pharma group. <\/em><br \/>\n        <br \/>\n        <em>\u00a9 February 2025 Ascendis Pharma A\/S.<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:1795.36px;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:895.672px;min-width:50%\">\n            <strong><br \/>\n              <u>Investor Contacts:<\/u><br \/>\n            <\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:895.688px;min-width:50%\">\n            <strong><br \/>\n              <u>Media Contact:<\/u><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Scott Smith<\/td>\n<td>Melinda Baker<\/td>\n<\/tr>\n<tr>\n<td>Ascendis Pharma<\/td>\n<td>Ascendis Pharma<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:ir@ascendispharma.com\" rel=\"nofollow\" target=\"_blank\">ir@ascendispharma.com<\/a>\u00a0\u00a0<\/td>\n<td>+1 (650) 709-8875<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\n            <a href=\"mailto:media@ascendispharma.com\" rel=\"nofollow\" target=\"_blank\">media@ascendispharma.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td>Patti Bank<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>ICR Healthcare<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>+1 (415) 513-1284<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:patti.bank@icrhealthcare.com\" rel=\"nofollow\" target=\"_blank\">patti.bank@icrhealthcare.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2RiOTJlODQtZGZiMy00ZDVlLTg0OGUtZjVmMmRhMWQxMmY2LTEwMjI4MDc=\/tiny\/Ascendis-Pharma.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors &amp; News section of the Ascendis Pharma website at https:\/\/investors.ascendispharma.com. A replay of the webcast will be available on this &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809324","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors &amp; News section of the Ascendis Pharma website at https:\/\/investors.ascendispharma.com. A replay of the webcast will be available on this &hellip; Continue reading &quot;Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-05T21:05:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025\",\"datePublished\":\"2025-02-05T21:05:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/\"},\"wordCount\":653,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/\",\"name\":\"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=\",\"datePublished\":\"2025-02-05T21:05:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/","og_locale":"en_US","og_type":"article","og_title":"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - Market Newsdesk","og_description":"COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors &amp; News section of the Ascendis Pharma website at https:\/\/investors.ascendispharma.com. A replay of the webcast will be available on this &hellip; Continue reading \"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-05T21:05:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025","datePublished":"2025-02-05T21:05:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/"},"wordCount":653,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/","name":"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=","datePublished":"2025-02-05T21:05:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Mzc5NiM2NzM4MDA1IzIwMTEyMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-full-year-2024-financial-results-and-provide-business-update-on-february-12-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809324"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809324\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}